RFA-AI-21-039: Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2021.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make $6.0 million in total. Applications closed on August 4, 2021.
From the official notice on Grants.gov, last changed May 7, 2021. Checked November 7, 2026.
- Total funding$6.0 million
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeUM1
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$5.7 million
- Typical project length5 years
- UM1, Research Project with Complex Structure Cooperative Agreement. A large research project with several connected parts, with substantial NIH involvement. Other open UM1 notices.
Projects funded under RFA-AI-21-039 were run by National Institute of Allergy and Infectious Diseases (NIAID, 2 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-21-039 in the NIH Guide.
Key dates
| Posted | May 7, 2021 |
|---|---|
| Deadline | August 4, 2021 |
| Archived by Grants.gov | September 9, 2021 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this funding opportunity announcement (FOA) is to support consortia to conduct research toward the prevention and cure of HIV. The Consortium for Innovative HIV Vaccine and Cure Research will establish a collaborative and integrated research program built around two areas of scientific focus: identification of the correlates and the mechanism(s) of protection of preventive vaccine(s) and the use of vaccines or other immune modalities in advancing cure research. Preclinical studies in nonhuman primate (NHP) models will be supported to investigate the mechanism(s), by which efficacious AIDS vaccines protect NHPs from initial infection or establishment of systemic infection, and will incorporate vaccines or other immune interventions into cure strategies in SIV or SHIV-infected NHPs with the objective of eliminating virus reservoirs or establishing elite control of virus replication. Research findings can be applied to improve HIV vaccines and cure strategies and further advancement toward evaluation in human clinical trials.
Funded under RFA-AI-21-039 so far
NIH funded 2 projects under RFA-AI-21-039 in fiscal 2022 to 2026, at 2 institutions. The median yearly award was $5.7 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection | Emory University | 2026 | $5.7 million |
| SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens | Duke University | 2026 | $4.0 million |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-21-039 still open?
No. It closed on August 4, 2021.
Who can apply for Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)?
Closed August 4, 2021. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $6.0 million in total.
Who has been funded under RFA-AI-21-039?
NIH RePORTER lists 2 projects funded under RFA-AI-21-039 in fiscal 2022 to 2026, at 2 institutions. The most were at Emory University, Duke University.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)
- Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
- Cellular Senescence Network (SenNet): SenNet Data Coordination and Integration Center (SenNet DCIC) (UM1 Clinical Trials Not Allowed)
- Systematic Characterization of Genomic Variation to Assess Effects of Individual Variants on Genome Function and Phenotype (UM1 Clinical Trials Not Allowed)
- Computational Modeling and Analysis of the Impact of Genomic Variation on Function (UM1, Clinical Trial Not Allowed)